Schering-Plough

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Completed

A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

Jul 14, 2026

Completed

Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis

Earlier

Aug 3, 2017FDAQvar — QVAR REDIHALER

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

6 patent groups across drugs · Source: FDA Orange Book

DrugExpires

QvarSep 7, 2028 Qvar9 patentsMay 18, 2031 QvarJan 1, 2032 Qvar5 patentsJan 26, 2038 Qvar2 patentsJan 25, 2039 Qvar2 patentsMay 5, 2041

Regulatory

Regulatory Timeline

198311 events

FDAAug 31

Celestone — BETAMETHASONE VALERATE

Application NDA018865 (NDA)

FDAAug 31

Celestone — BETAMETHASONE VALERATE

Application NDA018870 (NDA)

FDAAug 31

Celestone — BETAMETHASONE VALERATE

Application NDA018864 (NDA)

FDAAug 31

Celestone — BETAMETHASONE VALERATE

Application NDA018860 (NDA)

FDAAug 31

Celestone — BETATREX

Application NDA018867 (NDA)

FDAAug 31

Celestone — BETAMETHASONE VALERATE

Application NDA018866 (NDA)

FDAAug 31

Celestone — BETATREX

Application NDA018862 (NDA)

FDAAug 31

Celestone — BETATREX

Application NDA018863 (NDA)

FDAAug 31

Celestone — BETAMETHASONE VALERATE

Application NDA018861 (NDA)

FDAJun 30

Celestone — BETADERM

Application NDA018839 (NDA)

FDAMar 24

Celestone — BETA-VAL

Application NDA018642 (NDA)

19872 events

FDADec 23

Qvar — VANCENASE AQ

Application NDA019589 (NDA)

FDAJul 27

Qvar — BECONASE AQ

Application NDA019389 (NDA)

19891 event

FDAJan 27

Eulexin — EULEXIN

Application NDA018554 (NDA)

19962 events

FDADec 24

Qvar — VANCERIL DOUBLE STRENGTH

Application NDA020486 (NDA)

FDAJun 26

Qvar — VANCENASE AQ

Application NDA020469 (NDA)

19991 event

FDAFeb 28

Celestone — LUXIQ

Application NDA020934 (NDA)

20001 event

FDASep 15

Qvar — QVAR 40

Application NDA020911 (NDA)

20141 event

FDADec 17

Qvar — QNASL

Application NDA202813 (NDA)

20171 event

FDAAug 3

Qvar — QVAR REDIHALER

Application NDA207921 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)